# Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

> **NCT02070744** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 40 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-661
- **DRUG:** Ivacaftor
- **DRUG:** Placebo matched to VX-661
- **DRUG:** Placebo matched to Ivacaftor

## Key facts

- **NCT ID:** NCT02070744
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-05-27
- **Final completion:** 2016-05-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070744, "Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02070744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*